Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Vaccine Timeline Expectations Have Become Unrealistic, Warns Porges

Herd Immunity Goal Could Be Years Away

Executive Summary

Despite record-breaking speed bringing several vaccine candidates into Phase I trials, the road ahead is likely to be much more treacherous and slow, warns one analyst.

You may also be interested in...



India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine

After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.

Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations

The clinical development head of Novartis Gene Therapies talks about the progress for SMA patients more than seven years after treatment began, and hopes of boosting outcomes by treating pre-symptomatic patients.

Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune

Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel